AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Genes & Diseases Article
PDF (826 KB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Rapid Communication | Open Access

Complement C1q induces the M2-polarization of tumor-associated macrophages in lung adenocarcinoma

Yuxiao Songa, Yang Fub, Jun Wangc, Jiazhuo Tanga, Jiaxin Yina, Zhimin Zhanga, Qibin Songa, Bicheng Zhanga( )
Cancer Center, Renmin Hospital of Wuhan University, Wuhan, Hubei 430061, China
Department of Oncology, Xiangyang Hospital, Hubei University of Chinese Medicine, Xiangyang, Hubei 441100, China
Department of Oncology, The First Affiliated Hospital of Shandong First Medical University, Jinan, Shandong 250000, China

Peer review under responsibility of Chongqing Medical University.

Show Author Information

References

【1】
【1】
 
 
Crossref Google Scholar
Genes & Diseases
Volume 11 Issue 4,
July 2024
Article number: 101093
DOI: 10.1016/j.gendis.2023.101093

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Cite this Report
Close
Close
Cite this article:
Song Y, Fu Y, Wang J, et al. Complement C1q induces the M2-polarization of tumor-associated macrophages in lung adenocarcinoma. Genes & Diseases, 2024, 11(4): 101093. https://doi.org/10.1016/j.gendis.2023.101093

709

Views

5

Downloads

9

Crossref

10

Web of Science

10

Scopus

0

CSCD
Received: 28 December 2022
Published: 13 September 2023
© 2023 The Authors.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).